Akebia Therapeutics Inc. buy Jefferies Financial Group Inc.
Start price
01.04.25
/
50%
€1.85
Target price
01.04.26
€5.54
Performance (%)
-23.35%
Price
12.12.25
€1.38
Summary
This prediction is currently active. The price of Akebia Therapeutics Inc. has decreased since the start of the prediction. Compared to the start price this results in a performance of -23.35%. This prediction currently runs until 01.04.26. The prediction end date can be changed by Jefferies_Financial_ at any time. Jefferies_Financial_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Akebia Therapeutics Inc. | 5.327% | 5.327% |
| iShares Core DAX® | 0.734% | -0.964% |
| iShares Nasdaq 100 | -2.686% | -2.409% |
| iShares Nikkei 225® | -2.261% | -4.038% |
| iShares S&P 500 | -1.346% | -1.510% |
Comments by Jefferies_Financial_ for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics, Inc. (NASDAQ: AKBA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $6.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat